Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in Chronic Hepatitis Delta Virus

summarizeSummary

Mirum Pharmaceuticals reported positive Phase 2b results for its investigational drug brelovitug in chronic hepatitis delta virus, meeting the primary endpoint with strong efficacy and a favorable safety profile.

check_boxKey Events

• Brelovitug Meets Primary Endpoint in AZURE-1 Study

  The Phase 2b portion of the AZURE-1 study for brelovitug, an investigational monoclonal antibody for chronic hepatitis delta virus (HDV), met its primary endpoint.

• Demonstrates Robust Antiviral Activity

  100% of patients in the 300 mg QW arm and 75% in the 900 mg Q4W arm achieved virologic response, compared to 0% in the delayed treatment arm. The primary composite endpoint was achieved in 45% and 35% of patients, respectively.

• Well-Tolerated Safety Profile

  Treatment with brelovitug was well tolerated across dose groups, with a favorable safety profile.

• Clear Path to Market

  Topline data from Phase 3 studies are expected in H2 2026, with potential BLA submission and commercial launch in the U.S. in 2027.

auto_awesomeAnalysis

Mirum Pharmaceuticals announced highly positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), a significant de-risking event for the program. The drug demonstrated robust antiviral activity, with 100% and 75% virologic response rates in the two dose arms, respectively, compared to 0% in the control group. The primary composite endpoint of virologic response and ALT normalization was also met with strong statistical significance. The favorable safety profile further supports its potential as a single-agent therapy. These results pave a clear path towards anticipated Phase 3 data in H2 2026 and a potential BLA submission and commercial launch in 2027, significantly enhancing the company's pipeline value and future revenue prospects.